

## Olympus launches new SeleCT™ Screening campaign

11 June 2025

### Highlights

- Olympus Corporation, one of the world's largest medical device companies, launches a new campaign for SeleCT™ Screening across the United States
- SeleCT™ Screening uses 4DMedical's lung density analysis technology on existing CT scans to identify candidates for the Olympus Spiration™ Valve System
- Full market release by Olympus creates large-scale U.S. deployment of 4DMedical's AI-based lung imaging for therapeutic screening

**Melbourne, Australia, 11 June 2025:** 4DMedical Limited (ASX: 4DX, "4DMedical", or the "Company"), a global leader in respiratory imaging technology, today announces the full market release of Olympus SeleCT™ Screening, a population-level emphysema screening program powered by 4DMedical's lung density analysis technology. The Olympus press release announcing the partnership can be accessed [here](#).

### Olympus launches AI-powered emphysema screening program powered by 4DMedical

Olympus Corporation, one of the world's largest medical device companies, has launched a new campaign to accelerate the uptake of SeleCT™ Screening across the United States. This AI-enabled solution reviews existing CT scans to identify patients with advanced emphysema who may be candidates for bronchoscopic lung volume reduction (BLVR), a minimally invasive intervention using endobronchial valves, such as the Olympus Spiration™ Valve System.

SeleCT™ Screening represents a large-scale commercial deployment of 4DMedical's AI-based lung density imaging analysis in a therapeutic screening context.

*"Technology like SeleCT™ Screening is an effective way to more quickly identify those who could most benefit from treatment and experience an improved quality of life"*, said Dr. Kyle Hogarth, Professor of Medicine and Director of Bronchoscopy and Interventional Pulmonology at University of Chicago Medicine.

*"We are excited for the full launch of an AI-powered tool to help connect patients to procedures that offer the possibility of an improved quality of life"*, said Swarna Alcorn, Business Unit Vice President, Respiratory, Olympus America.

### Commercial and clinical significance for 4DMedical

The full market release of Olympus' SeleCT™ Screening program:

- Establishes Olympus as a key channel partner, scaling 4DMedical's lung analysis technology across major U.S. health systems.
- Unlocks new patient identification workflows using existing CT infrastructure, without requiring additional scanning or tracer agents.
- Reinforces 4DMedical's expanding clinical utility in early detection, disease stratification, and therapy enablement.



Chronic obstructive pulmonary disease (COPD) affects nearly 16 million American adults, with more than 3 million of those diagnosed specifically with emphysema. COPD remains critically under-diagnosed, with studies showing that as many as 80% of adults with COPD worldwide are undiagnosed.

This partnership delivers a practical solution to address the global problem of COPD underdiagnosis and expands 4DMedical's presence in interventional respiratory care, an area of significant unmet need and commercial growth opportunities.

**4DMedical MD/CEO and Founder Andreas Fouras said:**

*"This campaign by Olympus represents a significant investment into our partnership with them. Through our combined efforts we are delivering real-world impact at scale—enhancing diagnosis, guiding therapy, and ultimately improving outcomes for patients living with emphysema."*

**–ENDS–**

Authorised by the 4DMedical Board of Directors.

**Contacts**

**Corporate**

Investor Relations

[investor.relations@4dmedical.com](mailto:investor.relations@4dmedical.com)

**Administration**

Company Secretary

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

**Media Enquiries**

[4Dmedia@4dmedical.com](mailto:4Dmedia@4dmedical.com)

**About 4DMedical**

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

At the heart of 4DMedical's innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical's solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of **Imbio**, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio's AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical's mission to redefine respiratory healthcare.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com)